On August 14, 2026, Turn Therapeutics Inc. entered into securities purchase agreements with accredited investors to issue and sell 135,000 shares of common stock at $10.00 per share, generating aggregate gross proceeds of $1.35 million. The transaction was conducted as a private placement under Section 4(a)(2) of the Securities Act and Regulation D, with registration rights granted to the investors. Turn Therapeutics Inc. operates in the biotechnology industry, focusing on drug discovery and development.
